| CT ID | Brief Title |
| NCT05104125 | Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris |
| NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM |
| NCT05107778 | Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV |
| NCT05118360 | Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH |
| NCT05118516 | Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects |
| NCT04965337 | Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects |
| NCT04843449 | Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects |
| NCT04845646 | DDI Study of ASC41 Tablets in HV and the PK, Safety and Tolerability in Subjects With NAFLD. |
| NCT04527250 | A Study of the Relative Bioavailability of ASC41 in Healthy Subjects |
| NCT04465890 | A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients |
| NCT04352361 | Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects |
| NCT04358523 | A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers |
| NCT04686994 | Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects |
| NCT04692025 | Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers |
| NCT04547894 | A Study of the Pharmacokinetics of ASC09F in Healthy Subjects |
| NCT04679129 | Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects |
| NCT03430830 | A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China |
| NCT03288636 | Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China |
| NCT03362814 | Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. |
| NCT03020134 | Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China |
| NCT03020082 | Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III |
| NCT03020095 | Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan |
| NCT03019991 | Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China |
For more information, please visit：https://www.clinicaltrials.gov/。
© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号 浙ICP备11050387号-1
